In a report released today, Michael Cherny from Merrill Lynch maintained a Buy rating on CVS Health (CVS), with a price target of $92. The company’s shares opened today at $65.25.
According to TipRanks.com, Cherny is ranked #800 out of 5110 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CVS Health with a $93.87 average price target, implying a 43.9% upside from current levels. In a report issued on December 19, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $96 price target.
.
See today’s analyst top recommended stocks >>
Based on CVS Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $47.27 billion and net profit of $1.39 billion. In comparison, last year the company earned revenue of $48.39 billion and had a net profit of $3.28 billion.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CVS Health Corp. engages in the provision of health care services. It operates trough the following segments: Pharmacy Services, Retail or Long Term Care, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise.
